UroStream

Dr. Biagio Antonio Maiorano from the Department of Medical Oncology, IRCCS San Raffaele Hospital (Milan, Italy), presented a sub-analysis of the ARON-1 study. This analysis evaluated the real-world incidence of grade 3–4 adverse events (AEs) and their clinical impact on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) receiving first-line immune checkpoint inhibitor (IO)-based combination therapies.

At a recent academic symposium, Professor Joan Palou from the Department of Urology, Universitat Autònoma de Barcelona, Spain, presented the latest subgroup analysis from the POTOMAC study. The presentation focused on the efficacy and safety of one year of durvalumab (D) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC) patients aged ≥65 years.

During a recent session on urological oncology, Professor A. Ślusarczyk from the Department of General, Oncological, and Functional Urology at the Medical University of Warsaw, Poland, presented the results of an international multicenter retrospective study. The study aimed to develop and validate a clinical predictive model to identify patients with high-grade non-muscle-invasive bladder cancer (NMIBC) who are at risk of BCG-unresponsiveness or disease progression following treatment.

At a recent international uro-oncology symposium, Dr. Takemura K. from the Department of Genitourinary Oncology at the Japanese Foundation for Cancer Research (JFCR), Ariake Hospital, presented findings from a multicenter retrospective study investigating the correlation between the time-of-day administration (ToDA) of first-line immune checkpoint inhibitors (ICIs) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).

During the recent academic conference, Professor Liangyou Gu from the People's Liberation Army General Hospital (PLAGH) presented the latest findings from a prospective, controlled, phase II study. The study evaluated the efficacy and safety of Disitamab Vedotin (DV/RC48), a HER2-targeted antibody-drug conjugate (ADC), combined with Tislelizumab (a PD-1 inhibitor) as adjuvant therapy for patients with HER2-expressing upper tract urothelial carcinoma (UTUC) following radical surgery.

During a recent academic session, Dr. Tao Zihao from Peking University First Hospital presented the preliminary results of a Phase II study evaluating the efficacy and safety of Disitamab Vedotin (RC48-ADC) in combination with radiotherapy for the adjuvant treatment of Upper Tract Urothelial Carcinoma (UTUC). This study provides a potential new therapeutic strategy for high-risk UTUC patients who are cisplatin-ineligible or refuse conventional chemotherapy

At a recent academic symposium, Dr. Xuanjun Guo (Peking University First Hospital) presented data from a multicenter real-world study evaluating the efficacy and safety of Disitamab Vedotin (RC48), a humanized anti-HER2 antibody-drug conjugate (ADC), administered as monotherapy or in combination with PD-1 inhibitors for high-risk non-muscle-invasive bladder cancer (HR-NMIBC). This study provides critical real-world evidence for patients seeking bladder-sparing alternatives.

The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most important global academic platforms in urology.

The 2026 ASCO Genitourinary Cancers Symposium (ASCO-GU) recently concluded successfully in San Francisco, USA. As one of the most influential global academic conferences in the field of genitourinary oncology, the meeting brings together the latest research advances and evolving clinical perspectives from around the world.

The 41st Annual Congress of the European Association of Urology (EAU26) was held in London, UK, from March 13–16, 2026, serving as one of the most influential academic platforms in global urology.